We also plan to assess the clinical utility of CNS-tau assays in PSP and CBD cohorts, where fluid biomarkers remain underdeveloped despite a clear need for improved diagnostics and therapeutic monitoring12. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.